Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227687 | 0.82 | — | — | |
| SCHEMBL828997 | 0.80 | — | — | |
| SCHEMBL72251 | 0.78 | — | — | |
| SCHEMBL9123557 | 0.76 | TSHR (0.38) | — | |
| SCHEMBL20721261 | 0.76 | TSHR (0.38) | — | |
| SCHEMBL75265 | 0.76 | — | — | |
| SCHEMBL15281530 | 0.74 | PNMT (0.48) | PNMTTAAR1DRD2DRD1DRD4 | |
| SCHEMBL15278765 | 0.74 | PNMT (0.48) | PNMTTAAR1DRD2DRD1DRD4 | |
| SCHEMBL2485508 | 0.74 | PNMT (0.48) | PNMTTAAR1DRD2DRD1DRD4 | |
| SCHEMBL15276726 | 0.74 | PNMT (0.48) | PNMTTAAR1DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042480-B1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-8013018-B2 | Aminoindane derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-2042480-A1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | GRIN3A, OPRL1, GRIN2A | PNMT 1283/4885TAAR1 56/4885DRD2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.